Last Price$68.62.5%
Market Cap$2,075.9M
P/E LTM
(40.0x)
5Y avg
(43.1x)
Biotechnology industry
median
(1.5x)
Stock quality & Intrinsic value
5/10
(0.8%) overvalued
Belite Bio, Inc P/E LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'22 | Dec'23 | |
|---|---|---|
| P/E LTM | (0.0x) | (41.2x) |
Overvalued or undervalued?
Check the intrinsic value for BLTE
and see if it's the right time to invest.
Belite Bio, Inc (BLTE) P/E LTM comparison analysis
General
LTM P/E LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Belite Bio, IncBLTE
(62.8x)
N/A
91.9%
N/A
Median Peer Set
(16.8x)
14.8%
(19.3%)
7.5%
BioMarin Pharmaceutical Inc.BMRN
31.5x
18.0%
139.3%
15.0%
Regeneron Pharmaceuticals, Inc.REGN
17.4x
8.3%
10.4%
31.1%
Royalty Pharma plcRPRX
16.9x
(3.8%)
(43.7%)
37.9%
United Therapeutics CorporationUTHR
11.5x
23.6%
25.7%
41.5%
BeiGene, Ltd.BGNE
(0.6x)
73.7%
467.1%
(35.9%)
BioNTech SEBNTX
(33.0x)
(77.4%)
(89.7%)
24.4%
Summit Therapeutics Inc.SMMT
(60.1x)
N/A
(68.7%)
N/A
Alnylam Pharmaceuticals, Inc.ALNY
(110.4x)
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals IncorporatedVRTX
(233.1x)
11.7%
N/A
(4.9%)
argenx SEARGX
(337.1x)
198.6%
(60.5%)
(24.1%)
BLTE key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.2 | 0.4 |
% margin | (0.0) 0.0% | (0.0) 0.0% | (0.2) 0.0% | (0.4) 0.0% |
| Operating Expenses | 5.7 | 9.8 | 12.8 | 31.7 |
| Research & Development Expenses (R&D) | 3.7 | 7.4 | 8.9 | 24.8 |
| Selling, General & Administrative Expenses (SG&A) | 2.1 | 2.4 | 4.0 | 6.8 |
% margin | (5.7) 0.0% | (9.8) 0.0% | (12.8) 0.0% | (31.7) 0.0% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.1 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | (5.8) | (9.7) | (12.6) | (31.6) |
% effective tax rate | 0.0 (0.0%) | 0.1 (1.3%) | (0.2) 1.4% | 0.0 (0.0%) |
% margin | (5.8) 0.0% | (9.8) 0.0% | (12.5) 0.0% | (31.6) 0.0% |
| EPS | (0.24) | (0.41) | (0.62) | (1.19) |
| Diluted EPS | (0.24) | (0.41) | (0.62) | (1.19) |
% margin | (5.7) 0.0% | (9.6) 0.0% | (12.4) 0.0% | (31.5) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Belite Bio, Inc's P/E LTM?
As of today, Microsoft Corp's last 12-month P/E LTM is (40.0x), based on the financial report for Sep 27, 2024 (Q3’2024). The average annual P/E LTM for Belite Bio, Inc have been (28.8x) over the past three years, and (21.6x) over the past five years.
2) Is Belite Bio, Inc's P/E LTM Good?
As of today, Belite Bio, Inc's P/E LTM is (40.0x), which is lower than industry median of (1.5x). It indicates that Belite Bio, Inc's P/E LTM is Good.